CAPRICOR THERAP. DL-001
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treat… Read more
Market Cap & Net Worth: CAPRICOR THERAP. DL-001 (4LN2)
CAPRICOR THERAP. DL-001 (F:4LN2) has a market capitalization of $1.49 Billion (€1.45 Billion) as of March 18, 2026. Listed on the F stock exchange, this Germany-based company holds position #7134 globally and #759 in its home market, demonstrating a 5.54% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying CAPRICOR THERAP. DL-001's stock price €26.65 by its total outstanding shares 54399282 (54.40 Million).
CAPRICOR THERAP. DL-001 Market Cap History: 2015 to 2026
CAPRICOR THERAP. DL-001's market capitalization history from 2015 to 2026. Data shows growth from $3.91 Million to $1.49 Billion (76.91% CAGR).
CAPRICOR THERAP. DL-001 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how CAPRICOR THERAP. DL-001's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 4LN2 by Market Capitalization
Companies near CAPRICOR THERAP. DL-001 in the global market cap rankings as of March 18, 2026.
Key companies related to CAPRICOR THERAP. DL-001 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
CAPRICOR THERAP. DL-001 Historical Marketcap From 2015 to 2026
Between 2015 and today, CAPRICOR THERAP. DL-001's market cap moved from $3.91 Million to $ 1.49 Billion, with a yearly change of 76.91%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €1.49 Billion | +7.03% |
| 2025 | €1.39 Billion | +89.21% |
| 2024 | €734.85 Million | +201.49% |
| 2023 | €243.74 Million | +23.51% |
| 2022 | €197.34 Million | +38.05% |
| 2021 | €142.95 Million | -16.34% |
| 2020 | €170.87 Million | +200.00% |
| 2019 | €56.96 Million | -76.92% |
| 2018 | €246.81 Million | +6214.29% |
| 2017 | €3.91 Million | 0.00% |
| 2016 | €3.91 Million | 0.00% |
| 2015 | €3.91 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of CAPRICOR THERAP. DL-001 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.49 Billion USD |
| MoneyControl | $1.49 Billion USD |
| MarketWatch | $1.49 Billion USD |
| marketcap.company | $1.49 Billion USD |
| Reuters | $1.49 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.